Related Experiment Video
Updated: Apr 14, 2026
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Anti-inflammatory Therapy With Simvastatin Improves Neuroinflammation and CNS Function in a Mouse Model of
Axel Stein1, Stijn Stroobants2, Volkmar Gieselmann1
1Institut für Biochemie und Molekularbiologie, Rheinische Friedrich-Wilhelms Universität, Bonn, Germany.
Abstract:
Metachromatic leukodystrophy (MLD) is a lysosomal storage disease caused by a functional deficiency of the lysosomal enzyme arylsulfatase A. The prevailing late-infantile variant of MLD is characterized by widespread and progressive demyelination of the central nervous system (CNS) causing death during childhood. In order to gain insight into the pathomechanism of the disease and to identify novel therapeutic targets, we analyzed neuroinflammation in two mouse models reproducing a mild, nondemyelinating, and a more severe, demyelinating, variant of MLD, respectively. Microgliosis and upregulation of cytokine/chemokine levels were clearly more pronounced in the demyelinating model. The analysis of the temporal cytokine/chemokine profiles revealed that the onset of demyelination is preceded by a sustained elevation of the macrophage inflammatory protein (MIP)-1α followed by an upregulation of MIP-1β, monocyte chemotactic protein (MCP)-1, and several interleukins. The tumor necrosis factor (TNF)-α remains unchanged. Treatment of the demyelinating mouse model with the nonsteroidal anti-inflammatory drug simvastatin reduced neuroinflammation, improved the swimming performance and ataxic gait, and retarded demyelination of the spinal cord. Our data suggest that neuroinflammation is causative for demyelination in MLD mice and that anti-inflammatory treatment might be a novel therapeutic option to improve the CNS function of MLD patients.
Insights
Neuroinflammation drives demyelination in Metachromatic Leukodystrophy (MLD). Treating MLD mice with simvastatin reduced inflammation, improved motor function, and slowed central nervous system (CNS) demyelination.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Metachromatic leukodystrophy (MLD) is a fatal lysosomal storage disease due to arylsulfatase A deficiency.
- The late-infantile MLD variant causes progressive central nervous system (CNS) demyelination in children.
Purpose of the Study:
- Investigate neuroinflammation's role in MLD pathogenesis.
- Identify potential therapeutic targets for MLD.
Main Methods:
- Analyzed neuroinflammation in mild (nondemyelinating) and severe (demyelinating) MLD mouse models.
- Measured microgliosis and cytokine/chemokine levels (MIP-1α, MIP-1β, MCP-1, ILs, TNF-α).
- Assessed simvastatin's effects on neuroinflammation, behavior, and demyelination in the severe model.
Main Results:
- Demyelinating MLD model showed increased microgliosis and cytokine/chemokine levels compared to the nondemyelinating model.
- Sustained MIP-1α elevation preceded demyelination, followed by MIP-1β and MCP-1.
- Simvastatin treatment reduced neuroinflammation, improved motor deficits, and slowed spinal cord demyelination.
Conclusions:
- Neuroinflammation is a key driver of demyelination in MLD.
- Anti-inflammatory strategies, like simvastatin, show therapeutic potential for MLD patients.
- Targeting neuroinflammation may improve CNS function in MLD.
More Related Videos
08:05Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice
Published on: March 1, 2017
04:55A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
Published on: May 11, 2022